Parkinson’s Disease - Pipeline Review, H1 2017 Market Report; Launched via MarketResearchReports.com

Parkinson’s Disease - Pipeline Review, H1 2017, provides an overview of the Parkinson’s Disease (Central Nervous System) pipeline landscape.

Parkinson’s disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson’s disease. Parkinson’s disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

Report Highlights

Parkinson’s Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Parkinson’s Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson’s Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson’s Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 32, 41, 5, 180, 48 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical, Discovery and Unknown stages comprises 1, 46, 14 and 1 molecules, respectively.

Parkinson’s Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson’s Disease (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Parkinson’s Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Parkinson’s Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Parkinson’s Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson’s Disease (Central Nervous System)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Parkinson’s Disease (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Parkinson’s Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 803 pages “Parkinson’s Disease - Pipeline Review, H1 2017” report covers Introduction, Parkinson’s Disease - Overview, Parkinson’s Disease - Therapeutics Development, Parkinson’s Disease - Therapeutics Assessment, Parkinson’s Disease - Companies Involved in Therapeutics Development, Parkinson’s Disease - Therapeutics Assessment, Parkinson’s Disease - Drug Profiles, Parkinson’s Disease - Dormant Projects, Parkinson’s Disease - Discontinued Products, Parkinson’s Disease - Product Development Milestones, Appendix. This report Covered Comapnies few are -  2-BBB Medicines BV, 4P Therapeutics LLC, AbbVie Inc, AC Immune SA, Acorda Therapeutics Inc, Adamas Pharmaceuticals Inc, Addex Therapeutics Ltd, Advinus Therapeutics Ltd, Aeolus Pharmaceuticals Inc, Biogen Inc, BioHealthonomics Inc, Biopharm GmbH, BrainStorm Cell Therapeutics Inc, Cantabio Pharmaceuticals Inc.

Please visit this link for more details: http://mrr.cm/UEu

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2017 - Visit at - http://mrr.cm/UEL

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2017 - Visit at - http://mrr.cm/UEb